米纳瑞斯制药

最新新闻

• 评级变动
  Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE), Mineralys Therapeutics, Inc. (MLYS) and Adagene (ADAG)
  TipRanks · 2026/8/13
• 评级变动
  Guggenheim Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $48
  \u5e02\u573a\u8d44\u8baf · 2026/5/19
• 评级变动
  Bank of America Securities Sticks to Its Buy Rating for Mineralys Therapeutics, Inc. (MLYS)
  TipRanks · 2026/8/12
• A Quick Look at Today's Ratings for Mineralys Therapeutics(MLYS.US), With a Forecast Between $40 to $56
  \u5e02\u573a\u8d44\u8baf · 2026/8/13
• 评级变动
  Analysts Are Bullish on These Healthcare Stocks: Mineralys Therapeutics, Inc. (MLYS), Context Therapeutics (CNTX)
  TipRanks · 2026/5/7
• Mineralys Therapeutics(MLYS.US) Director Sells US$3.01 Million in Common Stock
  \u5e02\u573a\u8d44\u8baf · 2026/9/25
• LifeSci Capital Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $54
  \u5e02\u573a\u8d44\u8baf · 2026/8/12
• 评级变动
  TD Cowen Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/5/7
• 评级变动
  A Quick Look at Today's Ratings for Mineralys Therapeutics(MLYS.US), With a Forecast Between $42 to $56
  \u5e02\u573a\u8d44\u8baf · 2026/5/8
• 评级变动
  Wells Fargo Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $55
  \u5e02\u573a\u8d44\u8baf · 2026/3/15
• 评级变动
  Analysts Have Conflicting Sentiments on These Healthcare Companies: Collegium Pharmaceutical (COLL), Myriad Genetics (MYGN) and Mineralys Therapeutics, Inc. (MLYS)
  TipRanks · 2026/5/8
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), Mineralys Therapeutics, Inc. (MLYS) and ArriVent BioPharma, Inc. (AVBP)
  TipRanks · 2026/6/4
• Form 144 | Mineralys Therapeutics(MLYS.US) Director Proposes to Sell 3.01 Million in Common Stocks
  \u5e02\u573a\u8d44\u8baf · 2026/9/23
• 评级变动
  Analysts Have Conflicting Sentiments on These Healthcare Companies: Intuitive Surgical (ISRG), Legend Biotech (LEGN) and Mineralys Therapeutics, Inc. (MLYS)
  TipRanks · 2026/8/12
• 评级变动
  Goldman Sachs Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $42
  \u5e02\u573a\u8d44\u8baf · 2026/6/4
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS) and Aprea Therapeutics (APRE)
  TipRanks · 2026/3/17
• 评级变动
  H.C. Wainwright Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $56
  \u5e02\u573a\u8d44\u8baf · 2026/8/12
• 评级变动
  TD Cowen Initiates Mineralys Therapeutics(MLYS.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/4/27
• 评级变动
  Analysts Are Bullish on Top Healthcare Stocks: CVS Health (CVS), Mineralys Therapeutics, Inc. (MLYS)
  TipRanks · 2026/5/7
• Mineralys Therapeutics, Inc. (MLYS) Gets a Buy From Wells Fargo
  TipRanks · 2026/8/12

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。